Unipolare Depression Langfassung - Versorgungsleitlinien.de

981. Özmen M, Özmen E. Treatment Approaches in Patients with Comorbid Depression and
Personality Disorder. Yeni Symposium: psikiyatri, nöroloji ve davranis bilimleri dergisi
2005;43(2):54-7.
982. Pilkonis PA, Frank E. Personality pathology in recurrent depression: nature, prevalence, and
relationship to treatment response. Am J Psychiatry 1988;145(4):435-41.
983. Hardy GE, Barkham M, Shapiro DA, Stiles WB, Rees A, Reynolds S. Impact of Cluster C
personality disorders on outcomes of contrasting brief psychotherapies for depression. J
Consult Clin Psychol 1995;63(6):997-1004.
984. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression:
meta-analysis of published studies. Br J Psychiatry 2006;188:13-20.
985. Ezquiaga E, Garcia A, Bravo F, Pallares T. Factors associated with outcome in major
depression: a 6-month prospective study. Soc Psychiatry Psychiatr Epidemiol
1998;33(11):552-7.
986. O'Leary D, Costello F. Personality and outcome in depression: an 18-month prospective
follow-up study. J Affect Disord 2001;63(1-3):67-78.
987. Peselow ED, Fieve RR, DiFiglia C. Personality traits and response to desipramine. J Affect
Disord 1992;24(4):209-16.
988. Sato T, Sakado K, Sato S, Morikawa T. Cluster a personality disorder: a marker of worse
treatment outcome of major depression? Psychiatry Res 1994;53(2):153-9.
989. Casey P, Meagher D, Butler E. Personality, functioning, and recovery from major depression.
J Nerv Ment Dis 1996;184(4):240-5.
990. Sareen J, Enns MW, Guertin JE. The impact of clinically diagnosed personality disorders on
acute and one-year outcomes of electroconvulsive therapy. J ECT 2000;16(1):43-51.
991. Duggan CF, Lee AS, Murray RM. Does personality predict long-term outcome in depression?
Br J Psychiatry 1990;157:19-24.
992. Russell JM, Kornstein SG, Shea MT, McCullough JP, Harrison WM, Hirschfeld RM, Keller MB.
Chronic depression and comorbid personality disorders: response to sertraline versus
imipramine. J Clin Psychiatry 2003;64(5):554-61.
993. Norden MJ. Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol
Psychiatry 1989;13(6):885-93.
994. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Fluoxetine trial in borderline personality
disorder. Psychopharmacol Bull 1990;26(1):151-4.
995. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients
with borderline personality disorder and comorbid dysthymia. Biol Psychiatry
1999;46(10):1429-35.
996. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and
haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993;50(5):377-85.
997. Parsons B, Quitkin FM, McGrath PJ, Stewart JW, Tricamo E, Ocepek-Welikson K, Harrison
W, Rabkin JG, Wager SG, Nunes E. Phenelzine, imipramine, and placebo in borderline
patients meeting criteria for atypical depression. Psychopharmacol Bull 1989;25(4):524-34.
998. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam,
carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988;45(2):111-9.
999. Stuart S, Simons AD, Thase ME, Pilkonis P. Are personality assessments valid in acute major
depression? J Affect Disord 1992;24(4):281-9.
1000. Diguer L, Barber JP, Luborsky L. Three concomitants: personality disorders, psychiatric
severity, and outcome of dynamic psychotherapy of major depression. Am J Psychiatry
1993;150(8):1246-8.
1001. Hoffart A, Martinsen EW. The effects of personality disorders and anxious-depressive
comorbidity in patients with unipolar depression and with panic disorder and agoraphobia. J
Personal Disord 1993;7:304-11.
© 2009 251